Vidutolimod

韦度利莫德

Report date: 2026/05/13 09:07:54

Base Information

Drug NameVidutolimod
Drug Alias NameCYT003 PolQbetaCYT 003 QbetaG10Virus-like particle-based cancer vaccine - CheckmateVLP-based cancer vaccine - CheckmateImmunodrug CYT003-QbG10, +[15] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > CpG ODNVaccines > Application > Therapeutic vaccineVaccines > Biological material > Viral vaccine
Mechanisms of ActionImmunostimulantsToll like receptor 9 agonists
TargetsToll like receptor 9
Therapy Area/IndicationsAllergic asthmaSkin MelanomaOropharyngeal Squamous Cell Carcinoma (OPSCC) +[21] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesUkraine +[15] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCytos Biotechnology Ag
China Registration ClassN/A

Develop Information

Active CompaniesArbutus IncXoma CorpCheckmate Pharmaceuticals Inc +[5] 
Inactive CompaniesCytos Biotechnology AgUniversity Of Southern CaliforniaEmory University +[4] 
Active IndicationsSkin MelanomaLymphadenopathyLiver Neoplasms +[5] 
Inactive IndicationsAllergic asthmaOropharyngeal Squamous Cell Carcinoma (OPSCC)Solid tumours +[16] 

Other Information

ATC CodeN/A
Related LinksN/A